Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ4 | P56696 | 3/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527518 | 0.86 | GAA (0.39) | KCNQ4KCNQ5CYP17A1P2RX3RXFP1 | |
| SCHEMBL15752719 | 0.82 | ABL1 (0.41) | KCNQ4KCNQ5CYP17A1GAA | |
| SCHEMBL22411865 | 0.81 | KCNQ4 (0.46) | KCNQ4KCNQ5CYP17A1BRAFP2RX3 | |
| SCHEMBL28660043 | 0.81 | KCNQ4 (0.42) | KCNQ4KCNQ5CYP17A1BRAFP2RX3 | |
| SCHEMBL12639204 | 0.80 | CYP17A1 (0.55) | CYP17A1MAPK14NAMPT | |
| SCHEMBL22411949 | 0.80 | KCNQ4 (0.47) | KCNQ4KCNQ5CYP17A1BRAFP2RX3 | |
| SCHEMBL28046953 | 0.80 | KCNQ4 (0.45) | KCNQ4KCNQ5CYP17A1BRAFP2RX3 | |
| SCHEMBL30002232 | 0.80 | KCNQ4 (0.45) | KCNQ4KCNQ5CYP17A1BRAFP2RX3 | |
| SCHEMBL31172075 | 0.80 | KCNQ4 (0.47) | KCNQ4KCNQ5CYP17A1BRAFP2RX3 | |
| SCHEMBL1055540 | 0.79 | AAK1 (0.39) | KCNQ4KCNQ5CYP17A1MAPK14BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3938369-A1 | TYK2 INHIBITORS AND USES THEREOF | Esker Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | KCNQ4 2575/4885KCNQ5 2527/4885CYP17A1 393/4885 |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | KCNQ4 2575/4885KCNQ5 2527/4885CYP17A1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.